In Vitro and in Vivo Activity of Amiodarone Against Ebola Virus

Julie Dyall, Joshua C. Johnson, Brit J. Hart, Elena Postnikova, Yu Cong, Huanying Zhou, Dawn M. Gerhardt, Julia Michelotti, Anna N. Honko, Steven Kern, Lisa Evans Dewald, Kathleen G. O'Loughlin, Carol E. Green, Jon C. Mirsalis, Richard S. Bennett, Gene G. Olinger, Peter B. Jahrling, Lisa E. Hensley

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


At the onset of the 2013-2016 epidemic of Ebola virus disease (EVD), no vaccine or antiviral medication was approved for treatment. Therefore, considerable efforts were directed towards the concept of drug repurposing or repositioning. Amiodarone, an approved multi-ion channel blocker for the treatment of cardiac arrhythmia, was reported to inhibit filovirus entry in vitro. Compassionate use of amiodarone in EVD patients indicated a possible survival benefit. In support of further clinical testing, we confirmed anti-Ebola virus activity of amiodarone in different cell types. Despite promising in vitro results, amiodarone failed to protect Guinea pigs from a lethal dose of Ebola virus.

Original languageEnglish (US)
Pages (from-to)S592-S596
JournalJournal of Infectious Diseases
StatePublished - Nov 22 2018
Externally publishedYes


  • amiodarone
  • antiviral
  • Ebola virus.

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'In Vitro and in Vivo Activity of Amiodarone Against Ebola Virus'. Together they form a unique fingerprint.

Cite this